IN BRIEF: GSK's ViiV Healthcare survey finds support for HIV regimen

GlaxoSmithKline PLC - West London-based pharmaceutical firm - ViiV Healthcare, the HIV joint ...

Alliance News 28 October, 2021 | 11:45AM
Email Form Facebook Twitter LinkedIn RSS

GlaxoSmithKline PLC - West London-based pharmaceutical firm - ViiV Healthcare, the HIV joint venture of GSK, Pfizer Inc and Shionogi & Co Ltd, says interim data from the Carisel study of healthcare teams and people living with HIV shows a positive attitude toward the long-acting HIV-treatment regimen of Vocabria and Rekambys. The study was conducted across Spain, France, Netherlands, Belgium and Germany through surveys and interview during the Covid-19 pandemic. ViiV's Vocabria, or cabotegravir, combined with Rekambys, or rilpivirine, from Johnson & Johnson's Janssen Pharmaceuticals Co is administered every two months under the regimen. ViiV Healthcare says the survey results suggest the regimen is "realistic and achievable in a variety of European healthcare settings".

Current stock price: 1,477.60 pence, up 2.5% on Thursday

Year-to-date change: up 10%

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,653.00 GBX 0.76
Johnson & Johnson 146.14 USD -0.46
Pfizer Inc 25.40 USD 0.55

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures